In the first study, disruption of WM tracts and cognitive decline was found after deep brain stimulation of the subthalamic nucleus (STN-DBS). The trajectories of electrodes in STN-DBS intersected with tracts involved in different cognitive domains [1].
A group of 51 consecutive PD patients underwent neuropsychological assessment before DBS and 6 months after in on-drug/on-stimulation condition. There was a decline in global cognitive evaluation and in selective cognitive domains including episodic verbal memory, executive functions, and phonemic and semantic verbal fluency. Decline in cued recall in verbal memory correlated with the proportion of lesions of the superior longitudinal fasciculus.
The second study showed that longitudinal evolution of macro- and microstructural damage follows different pathways in PD. Most of all, macroscopic damage, in vivo assessed by structural MRI, might provide a sensitive biomarker of disease progression in PD [2].
The 154 participating PD patients received clinical assessment, cognitive evaluation, and an MRI scan once a year over a period of 48 months. At baseline, diffusion tensor imaging (DTI) metrics differed significantly between total and normal appearing WM (NAWM) (P≤0.001). During follow-up, Unified Parkinson Disease Rating Scale (UPDRS)-III score and WM lesion volume (both P<0.001) significantly progressed. Longitudinal differences of mean, axial, and radial diffusivity values significantly correlated with UPDRS-III and Addenbrooke Cognitive Examination total score. Regression analyses showed a significant interaction between axial diffusivity and Mini-Mental State Examination (MMSE) and UPDRS-III score, both in total WM and in NAWM.
The authors concluded that, even though not evident macroscopically, NAWM appeared to be damaged. Microstructural damage at baseline was associated with cognitive and motor status. No such association was found for longitudinal evolution of NAWM microstructural damage.
- Costentin G, et al. Abstract O1022, EAN 2020.
- Scamarcia PG, et al. Abstract O3010, EAN 2020.
Posted on
Previous Article
« Sleep disorders mark PD progression Next Article
Letter from the Editor »
« Sleep disorders mark PD progression Next Article
Letter from the Editor »
Table of Contents: EAN 2020
Featured articles
Alzheimer's Disease and Other Dementias
Non-Alzheimer’s disease pathophysiology in the elderly
Novel genetic association with resistance to ERC tau deposition
Diastolic dysfunction novel risk factor for cognitive impairment
Epilepsy
Avoidable epilepsy-related mortality remains high
How genetic testing can contribute to epilepsy management
Cenobamate effective in focal epilepsy
Sustained seizure reductions with cannabidiol for Lennox-Gastaut syndrome
Prevalence of autoantibodies in epilepsy almost 10%
Parkinson's Disease
White matter matters in Parkinson’s disease
Sleep disorders mark PD progression
Directional DBS superior to omnidirectional DBS
Stroke
Benefits of statins to prevent stroke outweigh risks
Extubation after thrombectomy: the sooner, the better
Thrombus location and length predictors of early neurological deterioration
Endovascular treatment in large vessel occlusion stroke patients treated with OAC
Early edoxaban may be safe after cardioembolic stroke
Headache and Pain
Small fibre pathology as biomarker for fibromyalgia
Migraine as a cyclical functional disorder
Reassuring real-world safety profile of 3 CGRP inhibitors
Long-term cardiovascular safety of erenumab
Real-world data for erenumab in Germany
Eptinezumab in chronic migraine and medication-overuse headache
Fremanezumab tolerability in cardiovascular patients with migraine
Effects of galcanezumab on health-related quality of life
Multiple Sclerosis
Imaging to evaluate remyelination and neuroprotection
Serum NfL predicts long-term clinical outcomes in MS
Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS
High NEDA rates after 2 years of ocrelizumab
Switching from natalizumab to moderate- versus high-efficacy DMT
Results of compounds in late stages of development
Alemtuzumab efficacy and safety data of over 9 years
Fampridine treatment results in routine clinical practice
Air pollution is a possible risk factor for MS
Neuromyelitis Optica Spectrum Disorder
Genetic association studies in NMOSD needed
Eculizumab in NMOSD: the PREVENT study
Long-term safety of satralizumab consistent with double-blind periods
Neuromuscular Disorders
Biomarkers predicting motor function in SMA
Sustained benefits of avalglucosidase alfa in late-onset Pompe disease
Efficacy and safety of rituximab in refractory MG corroborated
Related Articles
September 8, 2020
News on AD biomarkers
September 9, 2020
Benefits of statins to prevent stroke outweigh risks
September 10, 2020
Small fibre pathology as biomarker for fibromyalgia
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com